GRAIL/$GRAL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About GRAIL

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Ticker

$GRAL
Primary listing

Industry

Biotechnology

Employees

1,000

ISIN

US3847471014
Website

GRAIL Metrics

BasicAdvanced
$1.7B
-
-$58.51
-
-

What the Analysts think about GRAIL

Analyst ratings (Buy, Hold, Sell) for GRAIL stock.

Bulls say / Bears say

GRAIL's Galleri test achieved a 45% year-over-year growth in U.S. revenue, with over 137,000 tests sold in 2024, indicating strong market adoption. (prnewswire.com)
The company has secured strategic partnerships, including integration with Quest Diagnostics and TRICARE coverage, enhancing accessibility and potential market reach. (prnewswire.com)
GRAIL ended 2024 with a strong cash position of $767 million, extending its financial runway into 2028, which supports ongoing operations and development. (prnewswire.com)
Despite revenue growth, GRAIL reported a net loss of $2 billion for the full year 2024, an increase of 38% compared to 2023, raising concerns about profitability. (prnewswire.com)
The company faces significant net losses and relies heavily on the Galleri test for revenue, indicating a lack of product diversification. (gurufocus.com)
GRAIL's recent spin-off from Illumina presents potential financial constraints and challenges in establishing independent operations. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

GRAIL Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GRAIL Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GRAL

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs